Results 141 to 150 of about 76,287 (256)

What Are the Impacts of GLP‐1 Drugs in Patients Needing Head/Neck Surgery?

The Laryngoscope, EarlyView.
Chelsea Gelboin‐Burkhart, Liam Gallagher, Bridget Ebert, Samir S. Khariwala   +3 more
wiley   +1 more source

Multifaceted burden of short bowel syndrome for patients and caregivers: The landmark survey

Nutrition in Clinical Practice, EarlyView.
Abstract Background Short bowel syndrome is a debilitating condition often requiring long‐term parenteral support to maintain hydration, nutrition, and survival. Methods As part of the noninterventional, cross‐sectional Landmark Survey study, we evaluated burdens associated with short bowel syndrome and parenteral support dependency from patient and ...
Jenny E. Harrison, Syed‐Mohammed Jafri, Roopa Vemulapalli, Vanessa Kumpf, Gail Mitchell, Mena Boules, Mindy M. Yang, Laurin Jackson, Jinyi Wang, Laurie Zografos, Daniel Wolin, Marion F. Winkler   +11 more
wiley   +1 more source

Anterior Cutaneous Nerve Entrapment Syndrome From Glucagon-Like Peptide-1 Receptor Agonist Injection. [PDF]

ACG Case Rep J
Singh N, Chaparro E, Shapiro JM, Husu EN.   +3 more
europepmc   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

Obesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu, Hao Dai, Huilin Tang, William T. Donahoo, Thomas J. George, Ramon C. Sun, Sizun Jiang, Aik Choon Tan, Yi Guo, Jonathan D. Licht, John M. Allen, Kelvin P. Lee, Jingchuan Guo, Jiang Bian   +13 more
wiley   +1 more source

Readability of AI-Generated Patient Information on Glucagon-Like Peptide-1 Receptor Agonists. [PDF]

JMIR Bioinform Biotechnol
Williams T, Bilic-Curcic I, Hurley J, Mummareddy H, Cigrovski Berkovic M, Canecki Varzic S, Gradiser M.   +6 more
europepmc   +1 more source

Incidental Resolution of Dopamine Agonist Induced Impulse Control Disorder with GLP‐1 Receptor Agonist

Movement Disorders Clinical Practice, EarlyView.
Hannah Kelly, Thomas Davis
wiley   +1 more source

The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective

Obesity, EarlyView.
ABSTRACT The off‐label use of glucagon‐like peptide‐1 receptor agonists (GLP‐1ra) among people without obesity and/or diabetes is rapidly expanding, despite a lack of clinical justification or safety data in this population. This Perspective explores the sociomedical dimensions of this trend, highlighting key research gaps and emerging hypotheses ...
Fernanda Baeza Scagliusi, Bruno Gualano, Pernille Andreassen, Cindi SturtzSreetharan, Sissel Due Jensen, Alexandra Brewis   +5 more
wiley   +1 more source

Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis

Obesity, EarlyView.
ABSTRACT Objective This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals. Methods A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Inês Rego de Figueiredo, Filipa Sofia Simas, Angela Ghiletchi, João Oliveira Torres, José Silva‐Nunes   +4 more
wiley   +1 more source

Administrative costs of prior authorizations for glucagon-like peptide-1 agonists. [PDF]

J Manag Care Spec Pharm
Pham D, Duby JJ, Setoudeh S, Knox S, Leahy K, Cruz D, Cutler T.   +6 more
europepmc   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source